Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial This study aimed to ...

The goal of the study was to evaluate the efficacy in lowering intraocular pressure (IOP) with a trabeculectomy and an amniotic membrane transplant (AMT) compared with the standard trabeculectomy with ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

Mitomycin C can be a cost-effective alternative to BCG as intravesical treatment for intermediate-risk nonmuscle-invasive bladder cancer at a time when BCG is in short supply. Mitomycin C has ...

Adding hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C to surgery for locally advanced colorectal cancer (CRC) significantly reduced the risk of locoregional recurrence, the ...

Methods. Narayanaswamy and colleagues conducted a prospective, nonrandomized, comparative study to compare the efficacy and safety of the Ologen™ (Optous, Roseville, California) collagen-matrix ...

The median number of BCG doses per patient was 9 in the combination arm and 16 in the monotherapy arm. Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin ...